What is Sight Sciences, Inc.'s market cap?

Sight Sciences, Inc. (SGHT) has a market capitalization of $278.6M and trades on NASDAQ.

What is Sight Sciences, Inc.'s revenue and profitability?

Sight Sciences, Inc. generated $79.6M in trailing twelve-month revenue with a net loss of $37.3M, representing a net margin of -46.8%. Gross margin stands at 86.2%, with free cash flow of -$25.4M. These figures are based on the Q1 2026 filing.

Who are Sight Sciences, Inc.'s competitors?

Sight Sciences, Inc.'s key competitors include Glaukos, Johnson & Johnson, Alcon, and others. These companies compete in similar markets and product categories.

Who does Sight Sciences, Inc. partner with?

Sight Sciences, Inc.'s notable partners include Peter’s Technology (Suzhou) CO LTD, Novitas Solutions, Inc., First Coast Service Options, Inc..

Where is Sight Sciences, Inc. headquartered?

Sight Sciences, Inc. is headquartered in United States of America and employs approximately 214 people. It has been publicly traded since 2021.

Sight Sciences, Inc.

SGHT

Market cap

$278.58M+56.2%

Revenue$79.6M+1.8%

Net income-$37.3M+24.6%

Free cash flow-$25.4M-2.6%

EPS (diluted)-$0.71+28.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$19.7MBeat by $1.2M EPS-$0.16Beat by $0.03

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$21.7M

EPS estimate-$0.15

Financials

Q1 2026

Income statement

See full

Revenue$19.7M+12.5%

Gross profit$17.0M+12.5%

Operating income-$12.4M+10.4%

Net income-$13.0M+8.3%

EPS (diluted)-$0.24+14.3%

Balance sheet

See full

Cash & equivalents$85.0M-21.9%

Total debt$40.9M+1.1%

Total equity$53.9M-30.6%

Total assets$109.7M-15.4%

Cash flow

See full

Operating cash flow-$7.0M+39.4%

CapEx$60.0K—

Free cash flow-$7.1M+38.9%

Valuation & ratios

Valuation

See full

Market cap$278.58M+56.2%

Enterprise value$234.51M+92.1%

P/S3.5×+1.1×

Profitability

See full

Gross margin86.2%+0.5pp

Operating margin-44.8%-10.2pp

Net margin-46.8%-9.6pp

FCF margin-31.9%+0.2pp

Returns & leverage

See full

Return on equity-56.6%+4.3pp

Debt / equity0.8×+0.2×

Current ratio5.9×-4.6×

Segments

By segment

See full

Surgical Glaucoma$18.3M+7.2%

Dry Eye$1.4M+244%

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

AbbVie$453.91B+36.3%

Alcon$32.8B-26.4%

Glaukos$8.9B+64.5%

Bausch + Lomb$5.8B+13.7%

Schering-Plough$696.1M—

Sight Sciences, Inc.$278.6M+52.2%

Iridex$15.5M-39.8%

By revenue growth

Glaukos+41.6%

AbbVie+9.5%

Bausch + Lomb+8.9%

Johnson & Johnson+8.1%

Sight Sciences, Inc.+1.8%

By net margin

Johnson & Johnson21.48%-3.5pp

AbbVie5.79%-1.5pp

Bausch + Lomb-3.21%+2.4pp

Glaukos-30.68%-9.2pp

Sight Sciences, Inc.-46.83%+16.4pp

Profile

Sight Sciences is a medical device company focused on developing and commercializing interventional technologies for the treatment of prevalent eye diseases, specifically glaucoma and dry eye disease. The company's core value proposition centers on restoring natural physiological functionality to the eye through minimally invasive procedures that address the underlying causes of disease. By providing intuitive tools for eye care professionals, the company aims to supplant conventional, less effective treatment paradigms with proactive interventional solutions.

Competitive position

A leading innovator in the MIGS and interventional dry eye markets, positioned as a comprehensive, implant-free alternative to traditional stents and pharmaceutical drops.

GeographiesUnited States, United Kingdom, Germany, European Union

Customer segmentsSpecialized medical practitioners, Surgical facilities

Business modelMedical device manufacturing, Consumable-driven razor-and-blade model

SuppliersContract manufacturers (specifically in China and Taiwan), Specialized laser micro-engineering services, Gamma sterilization providers, Third-party logistics providers

CustomersAmbulatory surgery centers, Hospital outpatient departments, Ophthalmology and optometry clinics, International medical device distributors

CountryUnited States of America

Listed2021

Employees214.0

CEOPaul Badawi

SectorHealthcare

IndustryMedical - Devices

Websitesightsciences.com

FilingsSEC EDGAR

Ask your AI about Sight Sciences, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sight Sciences, Inc.'s market cap?: Sight Sciences, Inc. (SGHT) has a market capitalization of $278.6M and trades on NASDAQ.
What is Sight Sciences, Inc.'s revenue and profitability?: Sight Sciences, Inc. generated $79.6M in trailing twelve-month revenue with a net loss of $37.3M, representing a net margin of -46.8%. Gross margin stands at 86.2%, with free cash flow of -$25.4M. These figures are based on the Q1 2026 filing.
Who are Sight Sciences, Inc.'s competitors?: Sight Sciences, Inc.'s key competitors include Glaukos, Johnson & Johnson, Alcon, and others. These companies compete in similar markets and product categories.
Who does Sight Sciences, Inc. partner with?: Sight Sciences, Inc.'s notable partners include Peter’s Technology (Suzhou) CO LTD, Novitas Solutions, Inc., First Coast Service Options, Inc..
Where is Sight Sciences, Inc. headquartered?: Sight Sciences, Inc. is headquartered in United States of America and employs approximately 214 people. It has been publicly traded since 2021.